Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MAD2L1
REST API REST API
Homo sapiens
MAD2L1 is differentially expressed in 319 experiments: 108 organism parts: bone marrow, cerebellum, ... (106 more);, 226 disease states: normal, cervical carcinoma, ... (224 more);, 110 cell types 323 cell lines 39 compound treatments and 74 other conditions.
Synonyms HSMAD2, MAD2
Orthologs mad2l1 (Danio rerio)   Mad2l1 (Mus musculus)   MAD2L1 (Gallus gallus)   MAD2L1 (Bos taurus)   Mad2l1 (Rattus norvegicus)   MAD2 (Saccharomyces cerevisiae)   mad2 (Drosophila melanogaster)   mad2l1 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term cytosol, mitotic sister chromatid segregation, spindle pole, cell division, M phase of mitotic cell cycle, protein binding, cytoskeleton, kinetochore, cytoplasm, mitotic cell cycle, negative regulation of apoptosis, condensed chromosome kinetochore, anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process, mitotic prometaphase, nucleus, chromosome, centromeric region, mitotic cell cycle checkpoint, mitosis, perinuclear region of cytoplasm, protein homodimerization activity, nuclear pore, chromosome, cell cycle checkpoint, mitotic cell cycle spindle assembly checkpoint, negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle, negative regulation of mitotic anaphase-promoting complex activity, positive regulation of mitotic cell cycle spindle assembly checkpoint, negative regulation of protein catabolic process, regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle
InterPro Term HORMA_DNA-bd
UniProt Accession Q13257, Q8IZX3, D6RJE3
Search EB-eye ENSG00000164109
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (36 experiments)

Factor Value U/D Experiments
MCF-7
1
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529, E-GEOD-5823
AGS
2
E-MTAB-37, E-GEOD-15460
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
MOLT4
2
E-MTAB-62, E-MTAB-37
YPAC
1
E-MTAB-37
H9
1
E-MTAB-62
317 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, ... (49 experiments)

Factor Value U/D Experiments
2
E-TABM-130, E-TABM-145
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-3204
immortalised T lymphocytes
1
E-GEOD-13909
primary fibroblast
1
E-MEXP-66
neurosphere cell
1
E-MEXP-551
104 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-GEOD-16363, ... (72 experiments)

Factor Value U/D Experiments
cervical carcinoma
4
E-MTAB-62, E-MEXP-1331, E-MTAB-37, E-GEOD-5823
colon carcinoma
3
E-MTAB-62, E-GEOD-3726, E-MTAB-57
control
3
E-GEOD-21912, E-GEOD-16363, E-GEOD-20295
glioblastoma
3
E-GEOD-6014, E-GEOD-4290, E-MTAB-37
lung adenocarcinoma
3
E-GEOD-2514, E-MEXP-231, E-MTAB-62
lymphoblastic leukemia MOLT-4
2
E-AFMX-5, E-TABM-145
220 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (27 experiments)

Factor Value U/D Experiments
control
3
E-GEOD-5339, E-GEOD-4006, E-GEOD-3284
none
4
6
E-MEXP-1601, E-TABM-782, E-GEOD-5824, E-GEOD-4600, E-GEOD-412, ... (10 experiments)
lipopolysaccharide
1
2
E-TABM-868, E-GEOD-3720, E-MEXP-1958
Cxcl12
1
E-GEOD-7307
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
sapphyrin PCI-2055
1
E-GEOD-6400
33 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-2034, ... (11 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-2666, E-MEXP-958, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-GEOD-21138, E-GEOD-19665, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, ... (10 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-TABM-321, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-TABM-440, E-GEOD-837, E-GEOD-1692, E-TABM-263, ... (13 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-2748

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (35 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-MEXP-561

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, ... (8 experiments)

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-43, E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, ... (7 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-TABM-43, E-GEOD-1561, E-GEOD-6532, ... (7 experiments)

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

Processing time: 0.486 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM